deg-32-106 prevented angiogenesis disturbance caused by the anti-CD36 antibodies. (A) HPVEC in Matrigel-coated wells were incubated with anti-CD36 sera (1:10, 1:40 dilution) in the absence or presence of deg-32-106. Diluted sera from naive mice were run as controls (control). (C) Thrombin (TR), 32-106, deg-32-106, or 32-106 together with mAb IV.3 against FcγRIIa was added to HPVEC as indicated. Mouse IgG was used as control. Scale bars, 100 µm. (B, D) Results from 3 experiments are presented. Data are expressed as mean ± standard deviation. Significance (*P < .05; **P < .005; and ***P < .0005) were analyzed by using a two-tailed unpaired Student t test.